You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0228 Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for ALL Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used: 3-Year Data from REPEAT Study

Article metrics

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - other biologic treatment
SAT0228 Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for ALL Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used: 3-Year Data from REPEAT Study

 

Online download statistics by month:

Online download statistics by month: June 2014 to December 2023

AbstractFullPdf
Jun 2014200
Jul 2014300
Aug 2014702
Sep 2014400
Oct 20141301
Nov 2014700
Dec 2014301
Jan 2015700
Mar 2015201
Apr 2015300
Jun 2015100
Jul 2015300
Aug 2015200
Sep 2015800
Nov 2015401
Dec 2015200
Jan 2016200
Mar 2016701
Apr 2016600
May 2016300
Jun 2016802
Jul 2016900
Aug 2016900
Sep 2016401
Oct 2016700
Nov 20167019
Dec 2016901
Jan 2017601
Feb 2017300
Mar 2017600
Apr 2017802
May 20171000
Jun 2017701
Jul 2017300
Aug 2017500
Sep 20171000
Oct 2017400
Nov 2017400
Dec 20171801
Jan 20181600
Feb 20184400
Mar 20182000
Apr 20184000
May 20183001
Jun 2018800
Jul 20181600
Aug 2018600
Sep 2018400
Oct 20182000
Nov 20181800
Dec 20181200
Jan 2019400
Feb 20191400
Mar 2019600
Apr 2019200
Sep 2020800
Oct 2020200
Dec 2020600
Jan 2021400
Feb 2021200
Apr 2021600
May 2021200
Oct 2021400
Nov 2021400
Dec 2021800
Feb 2022200
Mar 2022800
May 2022600
Jul 20221500
Aug 20221000
Sep 2022400
Oct 2022600
Nov 2022800
Dec 2022600
Feb 2023400
May 2023600
Jul 2023200
Aug 2023600
Sep 2023400
Nov 2023300
Dec 20231000
Total632036